In the frame of the agreement with Interferon Medical Use SA in Collina
d’Oro, Switzerland, a 100% affiliate of mondoBIOTECH Holding AG, Bachem provides its
comprehensive know how on peptides and its longstanding experience in the manufacture of
peptides and finished pharmaceutical products. Bachem will receive unlimited access to the
comprehensive and further increasing number of development projects of mondoBIOTECH for
the treatment of rare diseases. Bachem will be in charge of providing peptide based active
ingredients required by mondoBIOTECH, sterile finished products to be used in clinical trials
as well as the appropriate regulatory documents. Further, Bachem is entitled to produce
current developmental orphan drugs for mondoBIOTECH, once approved.

“As a global company located in Switzerland, we very much look forward to the opportunity of
jointly manufacturing products ‘made in Switzerland’ with Bachem, the world leader in
peptides,” said Fabio Cavalli, CEO and Chief Business Architect of mondoBIOTECH.
Walter Isler, Head of Marketing and Sales at Bachem AG, commented: “The agreed
cooperation is another step in our longstanding successful collaboration with mondoBIOTECH
and offers Bachem additional market potential. On the basis of this agreement, Bachem gets
access to a multitude of peptide projects and thereby also further broadens its competency in
the manufacture of sterile finished products. Bachem is pleased to be strategic partner of
mondoBIOTECH and to support the company in its fight against rare diseases.”